0001567619-22-003042.txt : 20220209 0001567619-22-003042.hdr.sgml : 20220209 20220209160641 ACCESSION NUMBER: 0001567619-22-003042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220207 FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peppe Jennifer CENTRAL INDEX KEY: 0001861060 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40604 FILM NUMBER: 22607225 MAIL ADDRESS: STREET 1: IMAGO BIOSCIENCES, INC. STREET 2: 329 OYSTER POINT BLVD. 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 325 5156 MAIL ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2022-02-07 0 0001623715 Imago BioSciences, Inc. IMGO 0001861060 Peppe Jennifer C/O IMAGO BIOSCIENCES, INC. 329 OYSTER POINT BLVD, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-02-07 4 M 0 7000 1.52 A 155809 D Common Stock 2022-02-07 4 M 0 6000 2.52 A 161809 D Common Stock 2022-02-07 4 S 0 7100 20.1776 D 154709 D Common Stock 2022-02-07 4 S 0 5900 20.8374 D 148809 D Stock Option (Right to Buy) 1.52 2022-02-07 4 M 0 7000 0.00 D 2029-04-09 Common Stock 7000 17094 D Stock Option (Right to Buy) 2.52 2022-02-07 4 M 0 6000 0.00 D 2021-01-01 2027-03-28 Common Stock 6000 73551 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The transaction was executed in multiple trades in prices ranging from $19.74 to $20.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $20.74 to $20.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Senior Vice President, Clinical Operations /s/ Hugh Rienhoff, as Attorney-in-fact for Jennifer Peppe 2022-02-09